- Home
-
Technical Platform
-
Services
- TCR-T Lead Sequence Development Service
- Immune CAR Cell Preparation Technology Service
- Antibody Coupled Drug Discovery Service
- Antibody Affinity Maturation Service
- Antibody Humanization Services
- Bispecific Antibody Development Services
- Antibody Protein Sequencing Service
- Antibody Affinity Determination Service
Antibody Drugability Assessment
- Nucleic Acid Aptamer Synthesis Service
- Nucleic Acid Aptamer Modification Service
- Nucleic Acid Aptamer Library Construction Service
- Bispecific Aptamer Development Service
- Protein Nucleic Acid Aptamer Screening Service
- Metal Ion Nucleic Acid Aptamer Screening Service
- Small Molecule Nucleic Acid Aptamer Screening Service
- Cell Nucleic Acid Aptamer Screening Service
- Peptide Affinity Maturation Services
- Peptide-Drug Conjugate (PDC) Development Services
- Stapled Peptide Development Services
- Targeted Peptide Library Screening Service
- Targeted Peptide Library Construction Service
Active Peptide Discovery Technology Service
- mRNA Antibody Production Services
- mRNA Immunogen Production Service
- DNA Immune Antibody Preparation Service
Animal Immunization Technology Services
-
Technical Support
- Structural Basis for Selectivity and Antagonism in GPCR-Nanobodies
- Novel Peptide-Drug Conjugate (PDC) Shows Efficacy in Hepatocellular Carcinoma Models
- Nanobody Expression in Insect Cells
- Nanobody Mammalian Cell Expression
- Single-chain Antibody Library Construction Technology Introduction
- Prokaryotic Expression of Nanobodies
- Cell Line Immunogen of Nanobody
- Construction of Single Chain Antibody Library
- Nano-antibody/Single Domain Antibody Library Construction Service
- Customized Nano-antibody Immunogen3
- Cracking the Immune System’s “Source Code”: Why Is B-Cell Technology the Ultimate Path to Antibody Discovery?
- Five Golden Areas of Single B Cell Technology
- How much do you know about ADC drug development?
- Novel Cancer Therapeutic Strategy: Development of Bispecific Antibody-Drug Conjugates
- Nveiling the Molecular and Immunological Drivers of Antibody-Drug Conjugates (ADCs) in Cancer Treatment
- A PBD Dimer-Containing Antibody-Drug Conjugate (KK2845) Targeting TIM-3-Expressing AML
- A Novel Approach for Cancer Therapy - Modulating TCR Complex Recruitment to the T Cell Antigen Coupler (TAC) Enhances TAC-T Cell Function
- Development of Therapeutic Monoclonal Antibodies for Disease Treatment
- Common Problems and Solutions of Prokaryotic Expression of Recombinant Protein
- Neutralizing Monoclonal Antibody Development Service FAQ
Special topic on antibody modification
- Bacteriophages, yeast, mRNA display: Who is the champion of the display technology?
- Breakthrough: Ultra-High Sensitivity Detection of Legionella Using an Aptamer-Based Electrochemical Sensor
- Construction of yeast hybrid library: Gateway technology
- Eukaryotic System-Based Targeted Drug Discovery Platform: Yeast Display Technology
- Common Problems and Solutions for Yeast Two-hybrid Experiments
- Yeast Two-hybrid Technique Related Issues
- Common Problems and Solutions of Yeast Display Technology
- Overview of Yeast Two Hybrid System Principle and Application
- Introduction to Yeast Display Antibody Screening Technology
- Overview of Yeast Display Technology
Yeast Display Technology Special Topic
- Stop Sticking with Hybridoma! A Primer on the Three Generations of Antibody Discovery Technology
- Rationale and Significance of Bispecific Antibody Development
- Protein Not Expressing? You Might Have Chosen the Wrong Tag!
- What to Do After Protein Purification? These Four Validation Methods You Must Know!
- Yeast Two-Hybrid Technology Reveals a Novel Mechanism of Wheat Disease Resistance: How TaPIR1 "Hijacks" TaHRP1 to Suppress Chloroplast Function?
- Yeast Hybrid Library Construction: Smart Technology
- New Molecular Interaction Technology: How Much Do You Know About Yeast Hybridization Technology?
- Antibody Affinity Testing(SPR)
- Hybridoma Gene Sequencing Process
- Antibody Affinity Detection (BLI)
Antibody Detection Service Topic
- Application of phage display (Part 2)
- Application of phage display (Part 1)
- Phage Display
- Technical Article: Detailed Guide to Phage Screening
- Frontiers in Targeted Drug Development: Comparison and Application of Multiple Peptide Screening Methods
- Revolutionary Advances in Single-Domain Antibody Development and Applications
- New Method for Discovering Targeted Drugs: Screening of Peptide Libraries Based on Phage Display Technology
- How much do you know about IgG, Fab, scFv, and VHH?
- Novel Targeted Tumor Therapeutics: Efficacy of a Peptide-Drug Conjugate (PDC) in a Hepatocellular Carcinoma Model
- Non-Invasive In Vivo Monitoring of PROTAC-Mediated Protein Degradation Using an Environment-Sensitive Reporter
Special Topic on Phage Display Technology
- Discovery of targeted nucleic acid small molecules: Cell-SELEX technology
- A Promising Novel Cancer Therapeutic Strategy: Aptamer-Drug Conjugates (ApDCs)
- A Novel Therapeutic Approach for Multiple Myeloma: Development of a CD38 and CD47 Bispecific Bipartopic Antibody
- A Novel Therapeutic Approach - CAR-M
- Application And Prospects of CAR-T Technology in Tumor Immunotherapy
- CAR-T Discovery Service
CAR-T Molecule Discovery Topic
- The Promise of Small Nucleic Acid Therapeutics: From Bench to Clinic as Next-Generation Medicines
- Issues Related to Aptamer Library Screening
- Introduction to Nucleic Acid Aptamer Library Screening Technology
- Overview of Aptamer Synthesis Technology
- Screening and optimization of nucleic acid aptamers
- Screening and Application of Peptide Aptamers
- Main Research Directions Progress and Challenges of Nucleic Acid Aptamer Screening Technology
- Research Progress of Protein Nucleic Acid Aptamer Screening
- Research Progress of Aptamer Screening-of Small Molecule Targets
- Nucleic Acid Aptamer Libraries Screening: an Efficient Method for Discovering Specific Binding Molecules
Molecular Biology Service Topics
-
Product Center
- Contact Us
TekBiotech is dedicated to providing scientists worldwide with high-quality CAR-M design and targeting validation services.
TekBiotech is dedicated to providing scientists worldwide with high-quality proteolysis targeting chimera development services.
TekBiotech is committed to providing scientists worldwide with high-quality technical services including targeted antibody discovery, antibody humanization, ADC design and conjugation, cell killing assays, and animal model experiments.
TekBiotech is committed to providing high-quality targeted drug development services and technical support to research institutions, companies, and pharmaceutical enterprises worldwide.
TekBiotech is committed to providing scientists worldwide with high-quality targeted small molecule antibody discovery services, as well as subsequent CAR/TCR design and construction, antibody humanization, antibody affinity maturation, cell killing assays, and animal model experiments.
TekBiotech provide high-quality VHH neutralizing monoclonal antibody development services globally.
TekBiotech provide high-quality drug monoclonal antibody development services for various antibody formats, including scFv, VHH, and Fab, to scientists globally.
TekBiotech offer comprehensive services for targeted peptide library construction and screening
TekBiotech provides one-stop services including gene cloning, vector construction and protein expression and purification to assist scientific researchers and biopharmaceutical companies.
TekBiotech has been committed to the research of yeast two-hybrid system (Y2H) for many years. TekBiotech's yeast two-hybrid system is composed of a library constructed based on the SMART method, yeast strains, rigorous reporter genes, and high expression vectors. It can be used to study the interaction and interaction of proteins and define the interaction domain of proteins.
